Zacks Research Downgrades Brainsway (NASDAQ:BWAY) to Hold

Brainsway (NASDAQ:BWAY) was downgraded by equities research analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a report issued on Tuesday,Zacks.com reports.

Other equities research analysts have also issued reports about the company. HC Wainwright restated a “buy” rating and set a $14.00 price target on shares of Brainsway in a research report on Friday, July 17th. New Street Research reissued a “buy” rating on shares of Brainsway in a research note on Friday, July 24th. Weiss Ratings restated a “buy (b-)” rating on shares of Brainsway in a report on Tuesday, July 21st. BTIG Research raised their target price on Brainsway from $18.00 to $20.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, Wall Street Zen raised Brainsway from a “hold” rating to a “buy” rating in a report on Sunday, August 2nd. Five analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $16.33.

Brainsway Price Performance

Brainsway stock opened at $16.60 on Tuesday. The stock has a fifty day moving average price of $15.08 and a two-hundred day moving average price of $14.33. Brainsway has a 52-week low of $6.25 and a 52-week high of $17.40. The firm has a market capitalization of $666.16 million, a P/E ratio of 47.43 and a beta of 1.24.

Brainsway (NASDAQ:BWAY) last announced its earnings results on Wednesday, August 12th. The company reported $0.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.10 by $0.04. The business had revenue of $17.11 million during the quarter, compared to analysts’ expectations of $16.54 million. Brainsway had a net margin of 15.68% and a return on equity of 12.28%. On average, equities research analysts predict that Brainsway will post 0.33 EPS for the current fiscal year.

Hedge Funds Weigh In On Brainsway

Several large investors have recently made changes to their positions in the company. Goldman Sachs Group Inc. raised its position in shares of Brainsway by 2.3% in the 4th quarter. Goldman Sachs Group Inc. now owns 25,738 shares of the company’s stock valued at $490,000 after acquiring an additional 589 shares during the period. Man Group plc grew its holdings in Brainsway by 4.5% during the fourth quarter. Man Group plc now owns 18,027 shares of the company’s stock valued at $343,000 after purchasing an additional 782 shares during the period. NewEdge Advisors LLC increased its stake in Brainsway by 7.4% in the third quarter. NewEdge Advisors LLC now owns 28,629 shares of the company’s stock valued at $431,000 after purchasing an additional 1,964 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. bought a new stake in Brainsway in the first quarter valued at approximately $40,000. Finally, Ballast Advisors LLC acquired a new stake in Brainsway in the first quarter worth $55,000. Institutional investors and hedge funds own 30.11% of the company’s stock.

Trending Headlines about Brainsway

Here are the key news stories impacting Brainsway this week:

• Positive Sentiment: Quarterly earnings beat expectations: BrainsWay reported second-quarter EPS of $0.14, versus the $0.10 analyst consensus, while revenue of $17.11 million exceeded estimates of $16.54 million. Revenue increased 35% year over year to a record level, and the company posted a 15.68% net margin. BrainsWay Reports Second Quarter 2026 Financial Results and Operational Highlights
• Positive Sentiment: Revenue guidance was raised or reaffirmed above consensus: Management guided for fiscal 2026 revenue of $68 million to $70 million, compared with the $67.8 million consensus estimate. The outlook supports expectations for continued demand for BrainsWay’s noninvasive deep transcranial magnetic stimulation systems. BrainsWay Earnings Report and Conference Call
• Positive Sentiment: Analyst price target increased: BTIG Research raised its target from $18 to $20 and maintained a Buy rating, implying additional upside based on the referenced $16.60 share price. BrainsWay Price Target Raised by BTIG
• Neutral Sentiment: Momentum is strong, but valuation warrants attention: BWAY is trading near its one-year high and above its 50-day and 200-day moving averages. However, its price-to-earnings ratio of 47.43 leaves the stock sensitive to any slowdown in growth or future earnings disappointments. Brainsway Sets New 1-Year High Following Strong Earnings
• Neutral Sentiment: Reported short interest was listed as zero shares, so the data does not indicate meaningful short-covering pressure or a significant short-interest overhang.

About Brainsway

Brainsway Ltd is a medical device company specializing in non-invasive neuromodulation therapies. Publicly traded on the NASDAQ under the symbol BWAY, the company develops and commercializes deep transcranial magnetic stimulation (Deep TMS) systems designed to treat a range of neuropsychiatric and neurological disorders. Brainsway’s technology aims to offer an alternative or complement to traditional pharmacological therapies by targeting precise brain regions with its patented coil designs.

The company’s flagship Deep TMS platform utilizes proprietary H-coil arrays engineered to reach deeper cortical structures than conventional TMS devices.